AMW Again Reports Record Financial Results 2023, CEO Philipp Karbach Becomes Shareholder, Investment Program For Employees Launched

Warngau, June 3, 2024

AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today reported financial results for the year ended December 31, 2023. AMW posted a 2023 consolidated record revenue of EUR 29.4 million and achieved operating profitability for the second consecutive year. In addition, the Company reported a partial change in its shareholder structure combined with an offer for employees to become a shareholder in AMW on attractive terms (“AMW Evolution program”).

AMW reported a 2023 consolidated record revenue of EUR 29.4 million, compared to EUR 22.8 million for the 2022 financial year (+29%), and achieved operating profitability for the second consecutive year. The rise in revenues was mainly driven by increased sales of AMW’s implants goserelin and leuprorelin as well as an upturn in revenues from manufacturing activities. Endomedica GmbH, AMW’s wholly owned subsidiary, and responsible for marketing leuprorelin as Leugon® in Germany, also contributed significantly to the Company’s overall revenues achieving the third consecutive sales record in a row.

At the beginning of 2024, a partial change to AMW’s shareholder structure has been implemented. AMW Beteiligungsgesellschaft mbH & Co KG, which is predominantly owned by CEO Philipp Karbach, has taken over 23.66% of AMW’s shares. In addition, the “AMW Evolution program” has been set up to offer an opportunity for employees to participate in the Company’s long-term success by acquiring a specified number of shares at attractive conditions.

“We are extremely proud to have successfully continued our growth trajectory also in the 2023 financial year,” commented Philipp Karbach, CEO of AMW. “Our strategic focus on biodegradable implants and our uncompromising commitment to customer orientation are paying off. To allow our employees to participate in AMW’s successful development, I have decided on the ‘AMW Evolution program’. This is a decisive step for us to focus the entire team even more on the successful implementation of our strategy and to give those the opportunity to become proud shareholders who give their best every day. I am very pleased with the positive response and the interest shown so far. It makes me proud to continue pursuing our strategy of providing high-quality medicines to patients worldwide together with my dedicated team as joint shareholders.”


About AMW:

AMW GmbH is a specialty bio-pharmaceutical company focused on biodegradable sustained-release drug delivery systems, providing patients and partners access to value-added medicines and cost-effective therapies. Based on its technology platform, the Company builds on a growing own and partnered development pipeline. AMW has two approved products, goserelin and leuprorelin implants, which are distributed worldwide through both local and global pharma partners. In Germany, leuprorelin is marketed as Leugon® by AMW’s wholly owned subsidiary Endomedica GmbH. To support pharma and biotech partners in the development and manufacturing of their products and life-cycle solutions, AMW uses its leading-edge formulation development expertise.

AMW is based in Warngau near Munich, Germany.

For further information please contact:

Eva Hoffmann
Phone: +49 8024 470999-0